Vigil Neuroscience Reports First Quarter 2023 Financial Results and Provides Business Update
10. Mai 2023 07:00 ET
|
Vigil Neuroscience, Inc.
- Partial clinical hold lifted by FDA on VGL101 - - Launched ALSPAware to provide access to no-cost genetic testing and counseling for ALSP - - Appointed distinguished biopharmaceutical industry...
Vigil Neuroscience Appoints Samantha Budd Haeberlein, Ph.D. to Board of Directors
09. Mai 2023 07:00 ET
|
Vigil Neuroscience, Inc.
WATERTOWN, Mass., May 09, 2023 (GLOBE NEWSWIRE) -- Vigil Neuroscience, Inc. (Nasdaq: VIGL), a clinical-stage biotechnology company committed to harnessing the power of microglia for the treatment of...
Vigil Neuroscience Launches ALSPAware to Provide Access to No-cost Genetic Testing and Counseling for Adult-Onset Leukoencephalopathy with Axonal Spheroids and Pigmented Glia (ALSP)
08. Mai 2023 07:08 ET
|
Vigil Neuroscience, Inc.
– New genetic testing initiative designed to enable improved patient diagnosis of ALSP, a devastating, rare genetic neurodegenerative disease – – Through ALSPAware, individuals and healthcare...
Vigil Neuroscience Announces FDA Has Lifted the Partial Clinical Hold on VGL101
30. März 2023 07:00 ET
|
Vigil Neuroscience, Inc.
WATERTOWN, Mass., March 30, 2023 (GLOBE NEWSWIRE) -- Vigil Neuroscience, Inc. (Nasdaq: VIGL), a clinical-stage biotechnology company committed to harnessing the power of microglia for the treatment...
Vigil Neuroscience to Present at Stifel 2023 CNS Days
22. März 2023 07:00 ET
|
Vigil Neuroscience, Inc.
WATERTOWN, Mass., March 22, 2023 (GLOBE NEWSWIRE) -- Vigil Neuroscience, Inc. (Nasdaq: VIGL), a clinical-stage biotechnology company committed to harnessing the power of microglia for the treatment...
Vigil Neuroscience Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Update
21. März 2023 07:00 ET
|
Vigil Neuroscience, Inc.
– Dosed first patient in IGNITE Phase 2 clinical trial to evaluate VGL101 in patients with ALSP – – Presented interim data from natural history study, ILLUMINATE, at Company-hosted ALSP KOL event...
Vigil Neuroscience Announces Multiple Presentations on Lead Indication ALSP at the 2023 American Academy of Neurology Annual Meeting
02. März 2023 16:00 ET
|
Vigil Neuroscience, Inc.
WATERTOWN, Mass., March 02, 2023 (GLOBE NEWSWIRE) -- Vigil Neuroscience, Inc. (Nasdaq: VIGL), a clinical-stage biotechnology company committed to harnessing the power of microglia for the treatment...
Vigil Neuroscience to Present at the 41st Annual J.P. Morgan Healthcare Conference
03. Januar 2023 07:00 ET
|
Vigil Neuroscience, Inc.
CAMBRIDGE, Mass., Jan. 03, 2023 (GLOBE NEWSWIRE) -- Vigil Neuroscience, Inc. (Nasdaq: VIGL), a clinical-stage biotechnology company committed to harnessing the power of microglia for the treatment...
Vigil Neuroscience Appoints David Gray, Ph.D., as Chief Scientific Officer and Announces Changes to Executive Team
15. Dezember 2022 16:01 ET
|
Vigil Neuroscience, Inc.
– Dr. David Gray brings nearly 20 years of preclinical and clinical research and drug development expertise in neurological diseases – – Dr. Spyros Papapetropoulos to depart Vigil to pursue a...
Vigil Neuroscience Announces First Patient Dosed in the IGNITE Phase 2 Clinical Trial to Evaluate VGL101 in Patients with ALSP
14. Dezember 2022 16:01 ET
|
Vigil Neuroscience, Inc.
CAMBRIDGE, Mass., Dec. 14, 2022 (GLOBE NEWSWIRE) -- Vigil Neuroscience, Inc. (Nasdaq: VIGL), a clinical-stage biotechnology company committed to harnessing the power of microglia for the treatment...